But Dr. Nathan was more direct: “If the patient is not achieving goals, I would stop Avandia and change the regimen.”
Dr. Buse disclosed no financial ties with either GlaxoSmithKline Inc., maker of rosiglitazone, or Takeda Pharmaceutical Co., maker of pioglitazone. Dr. Goldstein has ties to both, whereas Dr. Nathan has received research support from GSK. All three have relationships with makers of other diabetes drugs.